1. Background
=============

Since 1990, stereotactic radiotherapy (SRT) has been widely available for the treatment of intracranial lesions. Recently, the use of SRT has gradually been expanded to include the treatment of extra-cranial lesions. In particular, SRT has been demonstrated as a safe and effective modality in the treatment of primary and metastatic lung tumors \[[@B1]\]. Initial clinical results were favorable, and local control rates around 90% have been reported \[[@B1]-[@B9]\]. Since May 2004, we have employed SRT for body trunk tumors using a simple body cast system at the University of Tokyo Hospital.

Regarding normal tissue, the use of a single dose rather than a conventional fractionated dose may increase the risk of complications. However, few cases with severe toxicity have been reported \[[@B10]\].

A few patients undergoing high-dose SRT suffered from RP, which was treated by administration of steroids. The percentage of total lung volume receiving greater than or equal to 20 Gy (V~20~) was reported to be a useful factor for RP in conventional fractions \[[@B11]\]. The useful dose volume histogram (DVH) factors were examined for predicting the occurrence of RP after SRT for lung tumors.

2. Methods
==========

2.1. Patients and tumor characteristics
---------------------------------------

From May 2004 to April 2006, 25 patients were treated with SRT using a stereotactic body cast system using a custom bed and low temperature thermoplastic material RAYCAST^®^(ORFIT Industries, Wijnegem, Belgium) at the University of Tokyo Hospital. All patients enrolled in this study satisfied the following eligibility criteria: 1) solitary or double lung tumors; 2) tumor diameter \< 40 mm; 3) no evidence of regional lymph node metastasis; 4) Karnofsky performance status scale ≧ 80% ; and 5) tumor not located adjacent to major bronchus, esophagus, spinal cord, or great vessels. Of the 25 patients, 16 had primary lung cancer, seven had metastatic lung cancer, and two had recurrent lung cancer. Ten patients were inoperable because of coexisting disease and one refused surgery. The primary lung cancers were staged as T1N0M0 in 15 and T2N0M0 in one. The primary sites of the metastases were the rectum, kidney, and ampulla of Vater in one each. A complete history was taken from all patients, and each received a physical examination, blood test, chest computed tomography (CT) scan, and whole-body positron emission tomography (PET) scan using FDG before treatment. Patient characteristics are summarized in Table [1](#T1){ref-type="table"}.

###### 

Details of patient characteristics

  **No.**   **Age**   **Sex**   **Primary site**   **Subject**   **Histology of target lesion**   **Chronic Lung Disorder**   **Inoperable reason**    **K-PS (%)**   **s KL (U/ml)**   **s SP-D (ng/ml)**   **VC (L)**   **FEV1.0 (L)**
  --------- --------- --------- ------------------ ------------- -------------------------------- --------------------------- ------------------------ -------------- ----------------- -------------------- ------------ ----------------
  1         75        M         lung               primary       Adenoca                          No                          reject                   90             wnl               wnl                  4.07         2.81
  2         83        M         lung               primary       Unknown                          No                          TAA/IHD                  90             wnl               wnl                  NA           NA
  3         50        F         rectum             metastasis    Adenoca                          post lobectomy              rectal ca.               90             wnl               wnl                  3.40         2.66
  4         77        M         lung               recurrence    SCLC                             emphysema                   SCLC-ED                  90             wnl               wnl                  NA           NA
  5         75        M         lung               primary       Adenoca                          No                          nephrotic syndrome       80             wnl               wnl                  NA           NA
  6         60        M         lung               metastasis    Adenoca                          post lobectomy              metastasis               90             743               wnl                  2.61         0.59
  7         79        M         lung               primary       SqCC                             emphysema                   colon ca./prostate ca.   90             wnl               wnl                  1.75         1.26
  8         79        M         ampulla of Vater   metastasis    Unknown                          No                          metastasis               80             wnl               wnl                  NA           NA
  9         69        M         lung               recurrence    Aenoca                           post partial resection      recurrence               90             wnl               wnl                  NA           NA
  10        84        M         lung               primary       SqCC                             No                          TAA                      70             wnl               wnl                  1.74         0.85
  11        81        M         lung               primary       Adenoca                          No                          M valve replacement      80             wnl               wnl                  3.19         2.30
  12        82        M         lung               primary       SqCC                             No                          prostate ca.             80             wn                wn                   2.50         1.75
  13        72        M         lung               metastasis    SqCC                             No                          metastasis               80             950               NA                   2.76         2.13
  14        80        M         lung               primary       Unknown                          emphysema                   HCC/colon ca.            80             NA                NA                   NA           NA
  15        80        M         kidney             metastasis    Unknown                          No                          Renal cell carcinoma     80             529               wnl                  NA           NA
  16        60        M         lung               metastasis    Carcinoma                        IP                          metastasis               80             852               NA                   4.01         3.24
  17        77        M         lung               primary       NSCLC                            IP                          IP                       80             1590              NA                   3.05         1.59
  18        68        M         lung               primary       Adenoca                          COPD                        COPD                     70             NA                NA                   NA           NA
  19        79        M         lung               primary       SqCC                             emphysema                   AAA                      90             520               NA                   NA           NA
  20        64        F         lung               primary       Adenoca                          No                          CRF/IHD                  90             wnl               wnl                  2.04         1.56
  21        76        F         lung               primary       SCLC                             No                          bladder ca./breast ca.   90             wnl               wnl                  2.17         1.59
  22        77        M         lung               primary       SqCC                             No                          diabetic nephropathy     80             wnl               wnl                  NA           NA
  23        78        M         lung               primary       NSCLC                            IP                          IP                       80             wnl               127                  NA           NA
  24        62        M         colon              metastasis    Unknown                          No                          colon ca.                90             wnl               wnl                  3.69         2.87
  25        78        F         lung               primary       Carcinoma                        IP/post lobectomy           post lobectomy           90             wnl               wnl                  1.54         0.99
                                                                                                                                                                                                                          
                                                                                                                                                                      (0--500)          (0--110)                          

AAA: abdominal aortic aneurysm, Adenoca: adenocarcinoma, ca.: cancer, COPD: chronic obstructive pulmonary disea

ED: extended disease, FEV: forced expiratory volume, HCC: hepatocellular carcinoma, IHD: ischemic heart disease, IP?

K-PS: karnofsky performance status scale, M valve: mitral valve, NA: not available, s: serum, TAA: thoracic aortic ane

RP: radiation pneumonitis, SCLC:small cell lung cancer, SP-D: surfactant protein-D, SqCC: squamous cell carcinoma,

In our clinical cases, five could not be histologically confirmed because the patients could not tolerate CT-guided biopsy and transbronchoscopic lung biopsy (TBLB). In these patients, the tumor diagnosis was confirmed clinically by a growing tumor on repeated CT scans and by exclusion of another primary tumor by clinical staging. None of the patients received concurrent chemotherapy with SRT. Additionally, no chemotherapy, which might affect the RP rates, was given prior to or immediately after SRT (until two months).

2.2. Planning procedure and treatment
-------------------------------------

The patient was positioned in a supine position on a custom bed. A body cast was made to broadly cover the chest to the abdomen during shallow respiration, and attached rigidly to the sidewall of the base plate.

The CT slice thickness and pitch were 1 mm each in the area of the tumor, and 5 mm each in the other areas. Each CT slice was scanned with an acquisition time of four seconds to include the whole phase of one respiratory cycle. A series of CT images, therefore, included the tumor and its respiratory motion. The axial CT images were transferred to a 3-dimension RT treatment-planning machine (Pinnacle^3^, New Version 7.4i, Philips). Treatment planning was performed using the 3D RTP machine. The target volume corresponded to the internal target volume (ITV) in Japan Clinical Oncology Group (JCOG) 0403 phase II protocol \[[@B12]\]. The CT images already included the internal motion because long scan time (four seconds) CT under free breathing (what is called, \"slow\" CT scan) was used \[[@B13],[@B14]\]. Spicula formation and pleural indentation were included within the ITV. The setup margin (SM) between ITV and the planning target volume (PTV) was 5 mm in all directions. Additionally, there was additional 5 mm leaf margin to PTV, according to JCOG0403 protocol, in order to make the dose distribution within the PTV more homogeneous. Two to 4 multi-leaf-collimator (MLC)-shaped non-coplanar static ports of 6-MV X-rays were selected to decrease mean lung dose (MLD), V~20~, and V~15~to below 18.0 Gy, 20%, and 25%, respectively, according to JCOG0403 protocol, although such numbers as V20 \< 20% and V15 \< 25% were valid for fractionation doses of about 2 Gy. We used no pairs of parallel opposing fields. The target reference point dose was defined at the isocenter of the beam. The collapsed cone (CC) convolution method was used as the dose calculation, in which the range of Compton electrons was better taken into account. In short, the convolution describes radiation interactions including charged particle transport, and calculates dose derived from CT density and patient set up information. The collapsed cone convolution method uses an analytical kernel represented by a set of cones, the energy deposited in which is collapsed onto a line (hence the name). The method is used to reduce computation time. In practice, the method utilizes a lattice of rays, such that each voxel is crossed by one ray corresponding to each cone axis. The primary beams were calculated heterogeneously and the scatter beams homogeneously as dose computation parameters. SRT was given with a central dose of 48 Gy in four fractions over 5--8 days in 6--7 fields by linear accelerator (SRL6000, Mitsubishi Electric Co., Tokyo) excluding two cases. Two patients (case no. 14 and 19) received 48 Gy in more than 4 fractionations (6 and 8 fractionations, respectively) (Table [2](#T2){ref-type="table"}) since the tumor located in the hilar (central) region. As to the peripheral dose of the PTV, we checked that 95% PTV volumes coverage dose (D95) was over 90% of the central dose. CT verification of the target isocenter was performed to ensure the correct target position and sufficient reproducibility of suppressing breathing mobility before each treatment session.

###### 

DVH characteristics in treatment planning.

  **No.**   **Tumor location**     **Isocenter Dose**   **BED~10~(Gy)**   **Beam**   **Co-pulanar**   **Collimators (mm)**   **Field size (mm^2^)**   **V~20~(%)**   **V~40~(%)**   **V~45~(%)**   **MLD (cGy)**   **D95 (cGy)**   **HI (%)**   **CI (%)**
  --------- ---------------------- -------------------- ----------------- ---------- ---------------- ---------------------- ------------------------ -------------- -------------- -------------- --------------- --------------- ------------ ------------
  1         peripheral             48Gy/4f              105.6             6          2                67 × 74                4958                     5.0            2.0            1.0            206             4408            126          171
  2         peripheral             48Gy/4f              105.6             6          2                40 × 61                2440                     5.0            2.0            1.0            488             4547            128          219
  3         peripheral             48Gy/4f              105.6             6          2                30 × 31                930                      1.0            0.5            0.3            172             4462            120          202
  4         peripheral             48Gy/4f              105.6             6          2                60 × 46                2760                     7.0            3.0            2.0            445             4325            128          147
  5         peripheral             48Gy/4f              105.6             6          2                48 × 63                3024                     3.0            2.0            1.0            298             4443            117          157
  6         peripheral             48Gy/4f              105.6             6          2                67 × 67                4489                     8.0            3.0            1.0            406             4435            123          197
  7         peripheral             48Gy/4f              105.6             6          2                49 × 57                2793                     8.0            2.0            1.0            510             4432            118          187
  8         peripheral             48Gy/4f              105.6             6          2                45 × 51                2295                     3.0            1.0            0.5            259             4468            125          182
  9         peripheral             48Gy/4f              105.6             6          2                55 × 60                3300                     7.0            2.0            1.0            404             4515            118          168
  10        peripheral             48Gy/4f              105.6             6          2                59 × 68                4012                     9.0            2.0            1.0            573             4511            122          170
  11        peripheral             48Gy/4f              105.6             6          2                69 × 68                4692                     7.0            2.9            2.0            404             4380            126          204
  12        peripheral             48Gy/4f              105.6             7          2                79 × 97                7663                     9.0            6.1            5.2            579             4355            134          169
  13        rt perihilar/central   48Gy/4f              105.6             6          2                51 × 51                2601                     7.0            2.7            1.9            585             4633            112          322
            lt perihilar/central   48Gy/4f              105.6             6          2                49 × 57                2793                     6.0            2.6            1.9            353             4629            110          257
  14        perihilar/central      48Gy/8f              76.8              6          2                45 × 63                2835                     7.0            1.0            0.5            568             4557            124          184
  15        peripheral             48Gy/4f              105.6             6          2                40 × 42                1680                     5.0            2.0            1.0            313             4617            109          282
  16        peripheral             48Gy/4f              105.6             6          2                70 × 54                3780                     10.0           5.0            3.0            791             4500            126          173
  17        peripheral             48Gy/4f              105.6             6          2                48 × 62                2976                     6.0            1.0            0.5            426             4405            121          310
  18        peripheral             48Gy/4f              105.6             6          2                55 × 53                2915                     4.0            1.0            0.5            291             4780            115          148
  19        perihilar/central      48Gy/6f              86.4              6          2                59 × 59                3481                     11.0           3.0            1.0            541             4835            139          170
  20        peripheral             48Gy/4f              105.6             7          4                49 × 46                2254                     11.0           1.0            0.5            321             4851            112          164
  21        peripheral             48Gy/4f              105.6             6          2                50 × 56                2800                     6.0            1.0            0.5            426             4602            118          192
  22        peripheral             48Gy/4f              105.6             6          2                55 × 57                3135                     7.0            2.0            1.0            440             4890            119          175
  23        peripheral             48Gy/4f              105.6             7          4                60 × 58                3480                     8.0            2.0            1.0            422             4585            112          130
  24        peripheral             48Gy/4f              105.6             6          2                35 × 34                1190                     2.0            0              0              230             4468            117          173
  25        peripheral             48Gy/4f              105.6             6          2                32 × 40                1280                     4.0            0.5            0              353             4591            107          153

BED: biologically effective doses, CI: conformity index, f: fractions, HI: homogeneity index, MLD: mean lung dose, Vx: irradiated lung volume more than × Gy

2.3. Evaluation of clinical outcome
-----------------------------------

After completing SRT, chest x-ray films and serial chest CT scans were checked for all cases to evaluate treatment outcomes at 2, 4, 6, 9, 12, 18, and 24 months after completion. Routine blood test results were also examined in all cases at the same time. Lactate dehydrogenase (LDH) and serum Krebs von den Lungen-6 (KL-6) were also collected at the same time as a serum marker of RP. The local tumor response was evaluated using the Response Evaluation Criteria in Solid Tumors Group \[[@B15]\]. Tumor response was assessed by follow-up chest radiography and CT scan. In accordance with WHO criteria, tumor response was defined as complete if all abnormalities that were anatomically related to the tumor disappeared after treatment, and defined as partial if the maximum size of these abnormalities decreased by ≧ 50%. Toxicities were evaluated using the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) version 3.0. The toxicity data was collected retrospectively from the patient files. The following grading system was assigned to the RP: Grade 1, asymptomatic (radiographic findings only); Grade 2, symptomatic and not interfering with activities of daily living (ADL); Grade 3, symptomatic and interfering with ADL or O~2~indicated; Grade 4, life-threatening (ventilatory support indicated), and Grade 5, death.

Maximum dose, minimum dose, D95, field size, and homogeneity index (HI) were evaluated (Table [2](#T2){ref-type="table"}). HI was defined as the ratio of maximum dose to minimum dose. In our institution, HI must be below 1.40 in order to keep the dose within the PTV more homogeneous. In analyzing the dose to the lung, the V~5~-V~20~, MLD, and conformity index (CI) were evaluated (Table [2](#T2){ref-type="table"}). V~5~-V~50~and MLD was calculated for both lungs. The lung volume minus the PTV (PTV excluded) was used as the volume of lung parenchyma. In this study, CI was defined as the ratio of treated volume (TV) (the definition of TV was the volume covered by minimum dose within PTV) to PTV (i.e. CI = TV/PTV) according to JCOG0403 protocol, although this concept might be old and be used hardly. This definition of the CI is the opposite comparing with the CI defined by Knoos *et al.*(CI = PTV/TV) \[[@B16]\]. The higher the CI values obtained indicated that the areas irradiated were less conformal. Three patients had lesions located in the hilar/central tumor region according to Timmerman *et al.*\[[@B10]\].

2.4. Statistical analysis
-------------------------

CI and MLD between RP positive and negative were compared using an unpaired multiple *t*-tests. Statistical significant was defined as *p*value of \<0.05.

3. Results
==========

The patients ranged in age from 50 to 84 years with a median of 77 years (73.8 ± 8.6 years). Female to male ratio was 4:21. The volumes irradiated over 5, 7, 10, 13, 15, 20, 30, 35, 40, 45, 50 Gy were designated as V~5~, V~7~, V~10~, V~13~, V~15~, V~20~, V~30~, V~35~, V~40~, V~45~, V~50~respectively. Nine patients had chronic lung disorders, and four were in a postoperative state. Four patients had emphysema, three had interstitial pneumonia (IP), and one had chronic obstructive pulmonary disease (COPD). The length of follow-up ranged from 10 to 28 months with a median of 17 months (16.1 ± 7.1 months). During the follow-up period, only two tumors showed local regrowth in the meaning of local control (Table [3](#T3){ref-type="table"}). The overall radiation treatment-time was five or 6 days in all cases excluding a single patient and the single patient was 8 days. The absolute volumes for every patient: ITV, PTV, the volume enclosed by the 48Gy total-isodose, the 24Gy-isodose-volume were shown in Table [4](#T4){ref-type="table"}.

###### 

Treatment results and RP grading

  **No.**   **Follow up (Months)**   **Dead or alive (cause of death)**   **Local control**   **Control out of field**   **RP grading**
  --------- ------------------------ ------------------------------------ ------------------- -------------------------- ----------------
  1         16                       dead (primary)                       PD                  PD                         G0
  2         19                       dead (aging)                         PR                  control                    G0
  3         20                       alive                                PR                  PD                         G1
  4         19                       alive                                PR                  control                    G1
  5         19                       alive                                CR                  control                    G1
  6         16                       alive                                PD                  PD                         G1
  7         15                       alive                                CR                  control                    G1
  8         10                       dead (primary)                       PR                  control                    G0
  9         14                       alive                                CR                  control                    G0
  10        4                        dead (aging)                         PR                  control                    G0
  11        10                       alive                                PR                  control                    G2 (2Mo)
  12        11                       alive                                PR                  control                    G1
  13        4                        dead (RP)                            CR                  control                    G5 (3Mo)
  14        11                       alive                                CR                  control                    G2 (5Mo)
  15        10                       alive                                PR                  control                    G1
  16        7                        dead (RP)                            CR                  PD                         G5 (6Mo)
  17        9                        alive                                CR                  control                    G3 (6Mo)
  18        9                        alive                                CR                  control                    G4 (9Mo)
  19        9                        alive                                PR                  control                    G1
  20        8                        dead (primary)                       CR                  control                    G1
  21        8                        alive                                CR                  control                    G0
  22        6                        dead (RP)                            CR                  control                    G5 (5Mo)
  23        7                        alive                                PR                  control                    G1
  24        3                        alive                                PR                  control                    G0
  25        2                        alive                                NE                  NE                         G0

CR: complete response, NE: not evaluate, PD: progressive disease, PR: partial response, RP: radiation pneumonitis, SD: stable disease

###### 

The absolute volumes for every patient: ITV, PTV, the volume enclosed by the 48Gy total-isodose, the 24Gy-isodose-volume

  **Case**   **ITV (cm^3^)**   **PTV (cm^3^)**   **V48 (cm^3^)**   **V24 (cm^3^)**
  ---------- ----------------- ----------------- ----------------- -----------------
  1          13.9              66.8              54.4              284
  2          10.1              40.1              25.9              108
  3          1.0               7.5               0.0               30
  4          9.6               34.9              6.7               141
  5          11.4              45.2              0.3               85
  6          34.2              85.1              22.8              166
  7          17.2              51.0              3.0               135
  8          9.7               33.7              10.5              57
  9          16.4              54.4              8.1               175
  10         30.8              81.9              25.3              258
  11         30.0              79.1              37.5              212
  12         126.9             239.4             98.4              263
  13 rt      5.0               20.5              16.5              123
  lt         6.4               26.4              15.6              114
  14         15.5              47.5              20.1              147
  15         5.0               10.2              3.4               109
  16         49.9              120.9             46.7              303
  17         5.1               29.4              6.4               128
  18         13.2              42.5              0.6               247
  19         36.2              85.0              6.8               238
  20         8.4               29.0              2.1               81
  21         9.0               29.6              1.7               103
  22         18.5              56.5              1.7               119
  23         17.3              50.8              1.8               153
  24         1.8               10.6              2.6               39
  25         1.7               10.5              0.4               36

Seven out of the 25 patients suffered from RP of grade 2 or more in the NCI-CTC version 3.0. All patients with RP had a cough, continuous fevers, severe dyspnea, and showed infiltrative changes in both irradiated and non-irradiated areas on chest CT (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). Three patients out of 25 treated with SRT died from a fatal RP. There were seven patients: one had RP at 2 months, one at 3 months, one at 9 months, two at 5 months, and two at 6 months. In all of the seven patients, pneumonitis spread out beyond the PTV. The overall incidence rate of RP grade 2 or more determined by the Kaplan-Meier method was 29.2% at 18 months after completing SRT (Figure [3](#F3){ref-type="fig"}). Various clinical as well as therapeutic factors were analyzed for their possible relationships to the incidence of RP (Table [2](#T2){ref-type="table"}). There were no significant relations between the incidence of RP and with or without co-morbidity lung disease (χ^2^test: *p*= 0.9400). Only two cases (22%) developed RP out of nine patients with co-morbidity lung disease. In all of the 25 patients, LDH levels remained normal during the follow-up period. Three of the seven patients with RP had high values of serum KL-6 before SRT, and the other four had normal serum KL-6 level. Additionally, RP had been observed in three patients who had high levels of serum KL-6 before SRT.

![Computed tomography (CT) image of radiation pneumonitis (RP) (patient No. 11).](1748-717X-2-21-1){#F1}

![CT image of RP (patient No. 13).](1748-717X-2-21-2){#F2}

![Kaplan-Meier plot of time from treatment until RP grade2 to 5. There were seven patients: one had RP at 2 months, one at 3 months, one at 9 months, two at 5 months, and two at 6 months.](1748-717X-2-21-3){#F3}

The high value of CI showed a significant correlation with the occurrence of RP, while MLD (Figure [4](#F4){ref-type="fig"}), field size, PTV volume, and V~5~, V~7~, V~10~, V~13~, and V~15~(p value according to unpaired *t*-test was 0.1966, 0.1658, 0.2351, 0.3831, and 0.3963, respectively) showed no correlations with RP. Additionally, V~20~, V~30~, V~35~, V~40~, V~45~, and V~50~showed no significant correlations with the incidence of RP, either (p value was 0.6768, 0.8369, 0.8318, 0.8044, 0.7544, and 0.9218, respectively) (Figure [5](#F5){ref-type="fig"}). Even when the volumes V~5~-V~50~were given in absolute units (cm^3^) for the lung parenchyma (PTV excluded), there were no significant correlations between V~5~--V~50~and the incidence of RP (Table [5](#T5){ref-type="table"}). The patients with RP had a mean CI of 222--66%, while the mean for patients without RP was 180--33% (*p*= 0.0394) (Figure [6](#F6){ref-type="fig"}). There was no significant correlation between both the ITV and PTV volume and the incidence of RP (*p*= 0.7415 and *p*= 0.7675, respectively).

![The correlation comparing the occurrence of RP grade 2 or more with MLD.](1748-717X-2-21-4){#F4}

![The correlation comparing the occurrence of RP grade 2 or more with V~20~-V~50~.](1748-717X-2-21-5){#F5}

![The correlation comparing the occurrence of RP grade 2 or more with CI.](1748-717X-2-21-6){#F6}

###### 

The correlation comparing the occurrence of RP with V5-V50

                   **V5**      **V7**      **V10**    **V13**    **V15**    **V20**    **V30**    **V35**   **V40**   **V45**   **V50**
  ----- ---------- ----------- ----------- ---------- ---------- ---------- ---------- ---------- --------- --------- --------- ---------
  *p*   value RP   0.2500      0.2422      0.3208     0.2742     0.2717     0.4063     0.5858     0.7557    0.8220    0.9307    0.4780
        with       744 ± 134   631 ± 117   495 ± 95   368 ± 70   307 ± 56   210 ± 39   124 ± 24   96 ± 18   75 ± 15   48 ± 11   1 ± 1
        without    604 ± 52    504 ± 47    400 ± 43   290 ± 32   244 ± 26   174 ± 20   108 ± 14   88 ± 13   70 ± 11   47 ± 9    4 ± 2

mean ± SD (cm^3^)

CI showed no significant correlations with V~5~-V~20~and MLD. CI correlated significantly with the ITV (both *t*-test and χ^2^test: *p*\< 0.0001).

No patient had NCI-CTC Grade 3 or 4 toxicities such as fatigue, dermatitis associated with radiation, dysphagia, esophagitis, and pain in chest wall.

4. Discussion
=============

Although extracranial stereotactic irradiation is an emerging treatment modality utilized by an increasing number of institutions in this field \[[@B1]-[@B4]\], only a few institutions have published their clinical results. SRT is accepted as a treatment method in medically inoperable non-small cell lung cancer or in patients who refused surgery. Promising results have been reported for this treatment method, with high local control rates and low incidence of complications \[[@B7],[@B17]-[@B21]\]. A multi-institutional prospective trial (JCOG 0403) is currently in progress in Japan. This paper describes the experience of treating 25 patients with small (\< 4 cm) lung tumors with four fractions of 12Gy. An unusually high rate of severe (grade 3 or more) RP (20%) and mortality (12%) was noticed and we are searching for reasons to explain these results, because we notice that these rates are far beyond other reported series. In this study, since the clinical data is collected retrospectively, the data is biased and there is a lack of information. Especially the lung function data of 11 patients (44%) are missing.

In our study, some of the patients started to suffer from \"pneumonitis\" almost 12 months after radiotherapy. These patients suffered from lung fibrosis plus pneumonia. RP is generally seen within 3 months of radiation and, in contrast, radiation fibrosis, which is thought to represent scar/fibrotic lung tissue, is usually a \"late effect\" seen \>3 months after radiation. These may be difficult to distinguish from each other. RP is a sub-acute (weeks to months from treatment) inflammation of the end bronchioles and alveoli. The clinical picture may be very similar to acute bacterial pneumonia with fatigue, fever, shortness of breath, non-productive cough, and a pulmonary infiltrate on chest x-ray. The infiltrate on chest x-ray should include the area treated to high dose, but may extend outside of these regions. The infiltrates may be characteristically \"geometric\" corresponding to the radiation portal, but may also be ill defined.

CI may be a useful DVH factor for predicting the occurrence of RP after SRT for lung tumors. Although the CI was first proposed in 1993 by the Radiation Therapy Oncology Group (RTOG) and described in Report 62 of the International Commission on Radiation Units and Measurements (ICRU), it has not been included in routine practice \[[@B16],[@B22]-[@B25]\]. The CI is a measure of how well the volume of a radiosurgical dose distribution conforms to the size and shape of a target volume, and is a complementary tool for scoring a given plan or for evaluating different treatment plans for the same patient. The radiation CI gives a consistent method for quantifying the degree of conformity based on iso-dose surfaces and volumes. Care during interpretation of radiation CI must always be taken, since small changes in the minimum dose can dramatically change the treated volume \[[@B16]\]. With the growth of conformal radiotherapy, the CI may play an important role in the future. However, this role has not yet been defined, probably because the value of conformal radiotherapy is just beginning to be demonstrated in terms of prevention of adverse effects and tumor control \[[@B26]-[@B29]\]. In our study, there was a significant association between CI with RP rate (*p*= 0.0394). A higher CI is less conformal. Figure [6](#F6){ref-type="fig"} appears to say that the CI should be less than 2.00 since the most patients (15/18 cases) without RP were covered. This is a reflection of the number of beams and the spreading out of the prescribed dose. It is recommended that efforts be directed to reduce CI (= TV/PTV) in treatment planning. For that purpose, the minimum irradiation dose within PTV should be raised to reduce the TV. CI is generally used as a criterion to evaluate treatment plan. It has no relation with the volume of the irradiated lung. From a radiotherapeutic/-biological point of view, it is not likely that CI has a true predictive value for development of RP. CI is related to volume receiving very high radiation dose (90 % of prescribed dose). Lung tissue is vulnerable even to low dose. Therefore parameters related to volumes receiving low doses (i.e. V~10~or MLD) are much more likely to correlate with toxicity. As the cases numbers were small, the co-relationship of CI and PR possibly may be coincident.

In our study, statistical analysis did not show significant association between MLD and RP rate, which were different from results of lung toxicity from conventional fractionation \[[@B11],[@B30],[@B31]\]. In our study, CI had no significant correlation with MLD. MLD was not a useful factor for predicting the occurrence of RP. V~5~rather than V~7~, V~10~, V~13~, V~15~, and V~20~had the strongest correlation with MLD, although in our study neither V~5~nor MLD was a useful factor for predicting RP.

In a similar study by Paludan *et al.*\[[@B32]\] reporting dose-volume related parameters in a similar number of patients (N = 28), no relationship between DVH parameters and changes in dyspnea was found. They found that deterioration of lung function was more likely related to the patient co-morbidity (COPD) than to dose-volume related parameters. However, in the present analysis, there were no significant relations between the incidence of RP and with or without co-morbidity lung diseases.

The levels of KL-6 \[[@B17],[@B33]-[@B35]\] and LDH are reported to be sensitive markers of RP, but in our study, both markers were not very sensitive. A few patients undergoing single high-dose SRT suffered from radiation pneumonitis, which was treated by administration of steroids. It is known that intense radiation changes and fibrosis without symptoms (Grade 1) will be found in the majority of patients after hypo-fractionated SRT. In addition, pneumonias develop regularly in these medically inoperable patients, and the combination of these can easily mislead to a diagnosis of RP. Misclassification in such a small number of patients will lead to a huge overestimation of the real incidence. In particular the fact that some of the patients already suffered from IP may have obscured the occurrence of RP. E.g. Figure [2](#F2){ref-type="fig"} is at \"best\" a patient suffering from bronchiolitis obliterans with organizing pneumonia (BOOP), with the bilateral infiltrates.

It is debatable whether V~20~can be applied to SRT in the same way as it is applied to conventional radiotherapy \[[@B11],[@B36]\]. Our \>20 Gy irradiated volume of the whole lung was 1.0--9.0% (average 4.83%), which was markedly smaller than that reported by Graham *et al.*\[[@B11]\]. In a previous study using whole-body irradiation, Wara *et al.*\[[@B37]\] demonstrated that eight Gy is the tolerance dose in the lung in single fractional irradiation. V~20~was defined for standard fractionation. Biologically equivalent dose (BED) would be about 6.7 Gy (α/β = 3) with 12 Gy per fractionation. Thus, V~5~and V~7~would be important factor.

Many studies \[[@B7],[@B18]-[@B20],[@B38]\] have reported no patients who showed RP of Grade 3 or more in lung SRT. Additionally, only low incident rate of grade 2 RP (2.4% \[[@B20]\], 3% \[[@B21]\], 5.4% \[[@B18]\], and 7.2% \[[@B39]\]) was reported. Hara *et al.*\[[@B17]\] at the International Medical Center of Japan reported that 3 of the 16 patients (19%) experienced RP of Grade 3 severity with SRT of 20--35 Gy in a single fraction. Belderbos *et al.*\[[@B39]\] suggested additional reductions of the security margins for PTV definition and introduction of inhomogeneous dose distributions within the PTV. Compared with these reports, the occurrence rate of RP was much higher in our institution. As for its cause, we submit that many patients in our study had poor respiratory function, many patients were judged as inoperable because of IP, and some cases had recurrent lung tumors after surgery. If the relative gantry angles and the number of beams were arranged more properly, the CI ratio would be made lower, since their factors probably are directly related to the CI. Additionally it is essential to use small fields. We set the leaves at 5 mm outside the PTV in order to make the dose distribution within the PTV more homogeneous. This may be the reason why we got so unacceptably high CI. We might have had to set the leaves at the margin of the PTV according to the ongoing Radiation Therapy Oncology Group protocols. There must be something wrong with either the way targets are irradiated. Clinical target volume including spicula formation (= ITV) + 5 mm ITV-PTV margin + 5 mm PTV-leaf margins might have been unnecessary large margins. However, our PTV (53.4 ± 47.0 cm^3^, median: 43.8 cm^3^) was almost equal to the PTV reported by Fritz *et al.*\[[@B38]\] (median: 45.0 cm^3^) without any symptomatic RP. It appears that in this study large volumes of lung parenchyma were irradiated to such high doses as the minimum dose within planning target volume (= high the TV and high CI value), which may explain the high incidence of lung toxicity.

Timmerman *et al.*\[[@B10]\] recently published a paper reporting of a high incidence of RP after SRT. They found an unacceptable high rate, if the tumor was located more centrally. In our study, this tendency was not seen (only one out of patients with severe RP had a central tumor).

Hope *et al.*\[[@B40]\] found that RP is correlated to the volume of the high dose region. These data (the value of CI and the incidence of RP had the strongest correlation) may support another hypothesis that RP probably has associations with high dose regions rather than with low dose regions (V~5~-V~20~). However, in our study, V~30~, V~35~, V~40~, V~45~, and V~50~showed no significant correlations with the incidence of RP, either. It may be no wonder that the CI does not show a relation with V~30~-V~50~, because the V~30~-V~50~depends on the absolute volume of the PTV, not on the CI. Only the treatment technique will show such correlation.

The use of multiple non-coplanar static ports achieved homogeneous target dose distributions and avoided high doses to normal tissues, despite the limitation of the beam arrangement from the use of the body frame and couch structure.

5. Conclusion
=============

In our institution, exceptionally high incidence of Grade 3--5 radiation pneumonitis after SRT for lung tumors was seen. Even in SRT, when large volumes of lung parenchyma are irradiated to such high doses as the minimum dose within planning target volume, the incidence of lung toxicity can become high. Further observations of the radiation changes in the lung after SRT are needed.
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